ICON Plc

Global provider of Outsourced Clinical Research

[ICON Plc @ICONplc]

ICON’s near-term, long-term and #netzero targets have been validated by #SBTi. In 2024 we decreased Scope 3 emissions 7.56% compared to 2022. Read more: https://t.co/bpWqcLn4tU

[ICON Plc @ICONplc]

Updated #biologics guidance signals a shift toward risk based #viralsafety, modern analytics and clearer clearance strategies. ICON’s John Muganga shares practical insights for manufacturers navigating these #regulatory changes. Read more in PharmTech. https://t.co/ZzVBOXCbiw

[ICON Plc @ICONplc]

Artificial intelligence is a powerful tool for enhancing trial accuracy, predictive modeling, and patient safety in vaccine innovation. Read the article to learn how AI is driving the next phase of clinical research: https://t.co/DEbWUelpdQ

[ICON Plc @ICONplc]

Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest #clinicaltrial regulatory updates current. https://t.co/g9mgkOsGKO

#regulatoryintelligence #regulatorycompliance #biotech #pharma #FoodandDrugAdministration #europeanmedicinesagency

[ICON Plc @ICONplc]

From complex trial designs to vast patient data, vaccine R&D faces significant operational hurdles. Discover how integrating AI can help developers solve legacy challenges in our article: https://t.co/osqcIbPco9

[ICON Plc @ICONplc]

Biosimilar regulations are evolving. New guidance could remove certain clinical study requirements and simplify global trials. Explore the implications: https://t.co/J0cDu9nTBK
#biosimilars #regulatoryaffairs #biopharma #clinicalresearch

[ICON Plc @ICONplc]

ICON is attending #CYTO 2026 in West Palm Beach, FL on 6–10 June. Visit us at booth #715 to connect with our flow cytometry experts and learn how our globally aligned capabilities support innovative and complex clinical trials. https://t.co/O5yZCLHdMm

[ICON Plc @ICONplc]

Vaccine development has traditionally taken years, but a technology-driven mindset is completely redefining the timeline. Explore how artificial intelligence is streamlining workflows and accelerating delivery in our article: https://t.co/8oh8FKUe91

[ICON Plc @ICONplc]

High interest does not equal smooth enrolment in psychedelic trials. Expect tighter criteria, more screen failures, and added complexity. A few practical considerations for sponsors: https://t.co/8NDgjpDvL6

[ICON Plc @ICONplc]

As #biosimilardevelopment shifts toward analytical comparability over clinical confirmation, CMC strategy is more critical than ever.

In PharmTech, Venkat Reddy Sunkara and Kim Salgado explore impacts on formulation, timelines and #regulatory success. https://t.co/rqowVj62sN

[ICON Plc @ICONplc]

Visit us at ASCO, booth #35093 to learn about ICON’s purpose built technology suite supports AI powered site identification, streamlined activation, contract drafting and site collaboration, helping sponsors move forward with efficiency and confidence. https://t.co/FQ8YAOBfdv

[ICON Plc @ICONplc]

Psychedelic trials show promise but bring operational risk. ICON’s support of a global programme across 150+ sites and 12 countries show what’s possible when complexity is planned for from day one. Learn more: https://t.co/ugGCJ9ZAQ0
#MentalHealthAwarenessMonth

[ICON Plc @ICONplc]

Meet the ICON team on 9 – 10 June at #OCTUK26 in London. We're gearing up for impactful discussions on advancing clinical trials. 13th Annual Outsourcing in Clinical Trials UK & Ireland 2026 - Arena International. https://t.co/j8aYk2OEuN

[ICON Plc @ICONplc]

Advancing #dermatology research: ICON co-authored the ViSENPsO® scale, a validated, user-friendly visually guided tool for evaluating nail #psoriasis severity to help improve consistency across clinical studies. https://t.co/ooEAdUQ2gw

#ClinicalResearch #HealthcareInnovation

[ICON Plc @ICONplc]

Honoured to be recognised by IMAPAC at ABEA 2026 for Site Innovation.
This award reflects the dedication of our APAC teams and our shared mission to accelerate clinical development for patients worldwide. https://t.co/ek308WNx9Z
#ClinicalResearch #Innovation #APAC

[ICON Plc @ICONplc]

May is #MentalHealthAwareness Month. Over the past 5 years ICON has conducted over 100 mood disorder studies involving over 13,900+ patients in key indications including Depression, Bipolar Disorder and Schizophrenia. Learn more. https://t.co/uRwKSaP26W

[ICON Plc @ICONplc]

#EMA and #FDA updates in March 2026 are set to streamline biosimilar development and reduce costs — but increase competition. What does this mean for your strategy?
Read more: https://t.co/c8tXZzzAfB
#biosimilars #drugdevelopment #clinicaltrials

[ICON Plc @ICONplc]

Designing FIH studies for oligonucleotide therapies?
Learn how to manage structural complexity, safety, and translational risk in our upcoming webinar.
Register here: https://t.co/JE93d2Qc3A

#EarlyPhase #ClinicalDevelopment #Oligonucleotides

[ICON Plc @ICONplc]

By easing the burden of participating in a clinical trial, In-Home Services improves patient recruitment and retention with a patient centric approach. Speak with ICON experts at #ASCO26, booth #35093 to learn more. https://t.co/FQ8YAOBfdv

[ICON Plc @ICONplc]

On #ClinicalTrialsDay, ICON recognises the researchers, site teams, and participants whose dedication keeps progress moving forward. We’re committed to supporting research that’s built on trust, quality, and patient focus. https://t.co/kxHZ2MttuD

#ResearchRising

[ICON Plc @ICONplc]

As products reach patients, #pharmacovigilance demands rise. Data grows, regulations evolve and post‑approval scrutiny intensifies.

ICON helps sponsors manage post‑marketing pharmacovigilance at scale, supporting #patientsafety and global compliance. https://t.co/XKrf04GQn4